Please read our student and staff community guidance on COVID-19
Skip to main content Skip to navigation


COVID-19 & MAMMO-50 Follow-up

Due to COVID-19 outbreak we will be monitoring those participants for whom their study mammogram has been/needs to be delayed due to limited services at the Trust and we will get back to sites with the list of those participants that needs their mammogram appointment to be re-scheduled.


Also, we would like to confirm there is no need to complete and return a Mammo-50 protocol deviation form for the deferred mammograms as a note to file will be in place to cover this.


As you are aware, the Mammo-50 annual follow-up can be conducted over the phone for those ladies not having a study mammogram in 2020.

Many thanks for your understanding and hard work!

Mammographic surveillance in breast cancer patients aged 50 years or older


Many thanks to all Participants, Research Teams and Principal Investigators for your hard work and support helping us to achieve this amasing milestone.

Mammo-50 is a multi-centre, randomised, controlled, phase III trial of annual mammography versus 2 yearly for conservation surgery patients or 3 yearly for mastectomy patients.

Also an observational cohort study was offered to those patients for whom the specialist or patient opts for standard mammography per local practice or immediate discharge to the screening programme or stopping mammography altogether.

An integrated feasibility study assessed the willingness for centres and patients to participate in the trial and explore reasons for non-randomisation of the cohort patients.

All patients are being asked to complete the Mammo-50 patient questionnaire booklet and followed up in terms of recurrence and survival in accordance with the protocol.



Mammo-50 is funded by the NIHR Health Technology Assessment Programme

The study is sponsored by

University Hospitals Coventry and Warwickshire and The University of Warwick will act as Co-Sponsor for the MAMMO-50 study.

The patient advocacy group Independent Cancer Patients' Voice has contributed to the study design, development of the patient information sheet and is represented on the Trial Management Group.


wms_gif.gifukcrn_logo.jpgNIHR gif













Study Logo

» FAQs


Please direct all general enquiries to:

mammo-50 at warwick dot ac dot uk

Maria Ramirez, Clinical Trial Manager

T: 02476 575 856

E: maria dot ramirez at warwick dot ac dot uk

Asha Bhandari, Trial Administrator

T: 02476 151 072

E: asha dot bhandari at warwick dot ac dot uk

John Lindley, Data Entry Clerk

T: 02476 573 368

E: j dot lindley dot 1 at warwick dot ac dot uk